[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","oufecqcs54p99uapntqdj0v28","revision",2,"title","Valion Bio 提交 8-K，披露新任董事会主席相关公告","originalTitle","8-K - Valion Bio, Inc. (0001787740) (Filer)","summary","Valion Bio 于 10 月 5 日发布新闻稿，介绍新任董事会主席 Thomas Jensen 的专业背景及其对公司未来的目标。公司在 8-K 中将该新闻稿作为附件 99.1 提交给 SEC。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-06T11:45:18.000Z","discoveredAt","2026-10-06T11:50:36.240Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",18,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f_xujEFbDD68",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","976054e7-c7bc-4f86-bee2-d543c7071b55","Valion Bio公布新任董事会主席",{"_72":73,"_15":74},"zh","

UNITED STATES
\nSECURITIES AND EXCHANGE COMMISSION
\nWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 5, 2026

Valion Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t Delaware \n\t\t\t	\n\t\t\t 001-41052 \n\t\t\t	\n\t\t\t 81-4016391 \n\t\t\t
\n\t\t\t (State or Other Jurisdiction of Incorporation) \n\t\t\t	\n\t\t\t (Commission File Number) \n\t\t\t	\n\t\t\t (IRS Employer Identification No.) \n\t\t\t

\n\t\t\t 1305 E. Houston Street, \n\n\t\t\t Building 1, Suite 311 \n\t\t\t
\n\t\t\t San Antonio, Texas \n\t\t\t		\n\t\t\t 78205 \n\t\t\t
\n\t\t\t (Address of Principal Executive Offices) \n\t\t\t		\n\t\t\t (Zip Code) \n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

Registrant’s Telephone Number, Including Area Code: 888 276-6888

\n\t\t\t

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t Title of each class \n\t\t\t		\n\t\t\t Trading Symbol(s) \n\t\t\t		\n\t\t\t Name of each exchange on which registered \n\t\t\t
\n\t\t\t Common Stock, par value $0.0001 per share \n\t\t\t		\n\t\t\t VBIO \n\t\t\t		\n\t\t\t The Nasdaq Stock Market LLC \n\t\t\t

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Matters.

On October 5, 2026, Valion Bio, Inc. (the “Company”) issued a press release highlighting the expertise and goals of new board chair, Thomas Jensen as relating to the future of the Company.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

Exhibit

\n\n\t\t\t

Number

\n\t\t\t

Description

\n\t\t\t

99.1

\n\t\t\t

Press Release, dated October 5, 2026.

\n\t\t\t

104

\n\t\t\t

Cover Page Interactive Data File (embedded within the Inline XBRL document).

\n\t\t\t

Forward-Looking Statements

This Current Report, including Exhibit 99.1 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibits 99.1 and 99.2 attached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the “SEC”), reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the SEC, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially and adversely from those expressed or implied by such forward-looking statements.

\n2\n

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

			\n\t\t\t VALION BIO, INC. \n\t\t\t

\n\t\t\t Date: \n\t\t\t	\n\t\t\t October 6, 2026 \n\t\t\t	\n\t\t\t By: \n\t\t\t	\n\t\t\t /s/ Dean Zikria \n\t\t\t
			\n\t\t\t Name: Dean Zikria \n\t\t\tTitle: Interim Chief Executive Officer \n\t\t\t

\n3\n

","zhKind","complete","VBIO","公司与财报","Nasdaq","aihot","/items/oufecqcs54p99uapntqdj0v28","https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/0001437749-26-032107-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791504000&sig=503fb7d170765eee","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791504000&sig=bd7a734cec863d9b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791504000&sig=e5a5cfd96e0c1fd2 96w","changelogVersion","2026-10-01T08:00"]